ResMed Aktie 321632 / US7611521078
233.20
USD
-0.62
USD
-0.27%
16:43:58
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
ResMed Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | ResMed Inc. | 1.00 | 1.92 | USD |
| 2023 | ResMed Inc. | 0.81 | 1.76 | USD |
| 2022 | ResMed Inc. | 0.80 | 1.68 | USD |
| 2021 | ResMed Inc. | 0.63 | 1.56 | USD |
| 2020 | ResMed Inc. | 0.81 | 1.56 | USD |
| 2019 | ResMed Inc. | 1.21 | 1.48 | USD |
| 2018 | ResMed Inc. | 1.35 | 1.40 | USD |
| 2017 | ResMed Inc. | 1.70 | 1.32 | USD |
| 2016 | ResMed Inc. | 1.90 | 1.20 | USD |
| 2015 | ResMed Inc. | 1.99 | 1.12 | USD |
Gewinn je Aktie- ResMed
| 6.9 24 | 6.1 23 | 5.3 22 | 3.2 21 | 4.3 20 | 2.8 19 | 2.2 18 |
Umsatz je Aktie- ResMed
| 31.8 24 | 28.6 23 | 24.3 22 | 21.8 21 | 20.3 20 | 18.0 19 | 16.3 18 |
KGV- ResMed
| 27.7 24 | 35.9 23 | 39.5 22 | 76.1 21 | 45.0 20 | 43.6 19 | 47.3 18 |
ResMed Inc.: Die Aktie (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 |
| Gewinn je Aktie unverwässert | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 |
| Gewinn je Aktie verwässert | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 |
| Dividende pro Aktie | 1.92 | 1.76 | 1.68 | 1.56 | 1.56 | 1.48 | 1.40 |
| Gesamtdividendenausschüttung in Mio. | 282.32 | 258.28 | 245.34 | 226.71 | 225.09 | 211.71 | 199.50 |
ResMed Inc.: Unternehmenskennzahlen (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 31.75 | 28.64 | 24.33 | 21.83 | 20.30 | 18.04 | 16.25 |
| KGV (Jahresendkurs, EPS unverwässert) | 27.66 | 35.90 | 39.55 | 76.09 | 44.98 | 43.58 | 47.26 |
| KGV (Jahresendkurs, EPS verwässert) | 27.66 | 35.90 | 39.55 | 76.09 | 44.98 | 43.58 | 47.26 |
| KGV (Jahresendkurs) | 27.66 | 35.90 | 39.55 | 76.09 | 44.98 | 43.58 | 47.26 |
| Dividendenrendite Jahresende in % | 1.00 | 0.81 | 0.80 | 0.63 | 0.81 | 1.21 | 1.35 |
| Eigenkapitalquote in % | 70.78 | 61.17 | 65.95 | 61.03 | 54.43 | 50.45 | 67.20 |
| Fremdkapitalquote in % | 29.22 | 38.83 | 34.05 | 38.97 | 45.57 | 49.55 | 32.80 |
ResMed Inc.: GuV (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 4’685.30 | 4’222.99 | 3’578.13 | 3’196.83 | 2’957.01 | 2’606.57 | 2’340.20 |
| Umsatzveränderung in % | 10.95 | 18.02 | 11.93 | 8.11 | 13.44 | 11.38 | 13.23 |
| Bruttoergebnis vom Umsatz | 2’608.78 | 2’313.64 | 1’993.23 | 1’808.02 | 1’687.69 | 1’461.65 | 1’315.78 |
| Bruttoergebnisveränderung in % | 12.76 | 16.07 | 10.24 | 7.13 | 15.47 | 11.09 | 13.90 |
| Operatives Ergebnis | 1’384.12 | 1’152.00 | 1’000.29 | 912.35 | 809.06 | 635.99 | 560.26 |
| Veränderung Operatives Ergebnis in % | 20.15 | 15.17 | 9.64 | 12.77 | 27.21 | 13.52 | 22.67 |
| Ergebnis vor Steuern | 1’264.80 | 1’101.66 | 960.48 | 883.66 | 733.09 | 518.85 | 521.31 |
| Veränderung Ergebnis vor Steuern in % | 14.81 | 14.70 | 8.69 | 20.54 | 41.29 | -0.47 | 24.49 |
| Ergebnis nach Steuer | 1’020.95 | 897.56 | 779.44 | 474.51 | 621.67 | 404.59 | 315.59 |
| Veränderung Ergebnis nach Steuer in % | 13.75 | 15.15 | 64.26 | -23.67 | 53.65 | 28.20 | -7.80 |
ResMed Inc.: Bilanz (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 2’008 | 2’622 | 1’735 | 1’842 | 2’090 | 2’035 | 1’005 |
| Langzeit Gesamtverbindlichk. pro Aktie | 7.47 | 12.67 | 7.14 | 6.39 | 10.27 | 10.30 | 3.46 |
| Eigenkapital | 4’864 | 4’130 | 3’361 | 2’886 | 2’497 | 2’072 | 2’059 |
| Veränderung Eigenkapital in % | 17.78 | 22.89 | 16.46 | 15.56 | 20.50 | 0.64 | 5.04 |
| Bilanzsumme | 6’872 | 6’752 | 5’096 | 4’728 | 4’587 | 4’108 | 3’064 |
| Veränderung Bilanzsumme in % | 1.79 | 32.49 | 7.78 | 3.07 | 11.68 | 34.07 | -11.66 |
ResMed Inc.: Sonstige Angaben (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 |
| Veränderung Gewinn je Aktie (unverwässert) in % | 13.55 | 14.61 | 63.42 | -24.19 | 52.35 | 27.89 | -8.65 |
| Gewinn je Aktie (verwässert) | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 |
| Veränderung Gewinn je Aktie (verwässert) in % | 13.68 | 14.83 | 63.60 | -24.09 | 52.42 | 27.76 | -8.67 |
| Anzahl Mitarbeiter | 9’980 | 10’140 | 8’160 | 7’970 | 7’770 | 7’240 | 5’940 |
| Veränderung Anzahl Mitarbeiter in % | -1.58 | 24.26 | 2.38 | 2.57 | 7.32 | 21.89 | -2.30 |
ResMed Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| ResMed Inc. | Quartalszahlen | 23.01.2025 |
| ResMed Inc. | Quartalszahlen | 24.04.2025 |
| ResMed Inc. | Quartalszahlen | 31.07.2025 |
| ResMed Inc. | Quartalszahlen | 23.10.2025 |
ResMed Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Hauptversammlung | Annual General Meeting | 21.11.2024 |
| Quartalszahlen | Q1 2025 Earnings Release | 24.10.2024 |
| Quartalszahlen | Q4 2024 Earnings Release | 01.08.2024 |
| Quartalszahlen | Q3 2024 Earnings Release | 25.04.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 24.01.2024 |
| Hauptversammlung | Annual General Meeting | 16.11.2023 |
| Quartalszahlen | Q1 2024 Earnings Release | 26.10.2023 |
| Quartalszahlen | Q4 2023 Earnings Release | 03.08.2023 |
| Quartalszahlen | Q3 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 26.01.2023 |
| Hauptversammlung | Annual General Meeting | 17.11.2022 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q4 2022 Earnings Release | 11.08.2022 |
| Quartalszahlen | Q3 2022 Earnings Release | 28.04.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 27.01.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.21 |
| The Vanguard Group, Inc. | 12.59 |
| Vanguard Group, Inc. (Subfiler) | 11.83 |
| State Street Corp. | 4.27 |
| BlackRock Fund Advisors | 3.82 |
| Walter Scott & Partners Ltd. | 3.17 |
| Vanguard Total Stock Market ETF | 3.16 |
| Vanguard 500 Index Fund | 2.65 |
| Geode Capital Management LLC | 2.63 |
| WCM Investment Management LLC | 2.39 |
| BlackRock Institutional Trust Co. NA | 2.18 |
| Vanguard Mid Cap Index Fund | 2.12 |
| Morgan Stanley Capital Services LLC | 2.09 |
| SPDR S&P 500 ETF Trust | 1.23 |
| Fidelity 500 Index Fund | 1.23 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 5’940 | 7’240 | 7’770 | 7’970 | 8’160 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.39 | 0.36 | 0.38 | 0.40 | 0.44 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1’066 | 1’145 | 1’523 | 1’575 | 1’931 |
| Summe Anlagevermögen | 1’998 | 2’962 | 3’064 | 3’153 | 3’164 |
| Summe Aktiva | 3’064 | 4’108 | 4’587 | 4’728 | 5’096 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’005 | 2’035 | 2’090 | 1’842 | 1’735 |
| Summe Eigenkapital | 2’059 | 2’072 | 2’497 | 2’886 | 3’361 |
| Summe Passiva | 3’064 | 4’108 | 4’587 | 4’728 | 5’096 |
Adresse
| 9001 Spectrum Center Boulevard, 92123 San Diego | |
| Telefon | +1 (858) 836-5000 |
| URL | http://www.resmed.com |
Management
|
Alastair Robertson
Chief Information Officer |
|
Amy Wakeham
Chief Investor Relations Officer |
|
Andrew Price
Chief Supply Chain Officer |
|
Bobby Ghoshal
Chief Commercial Officer-SaaS |
|
Brett A. Sandercock
Chief Financial Officer |
|
Carlos M. Nunez
Chief Medical Officer |
|
Carol J. Burt
Independent Director |
|
Christopher J. DelOrefice
Independent Director |
|
Dawn Haake
Chief Quality Officer |
|
Desney Tan
Independent Director |
|
Geoff Neilson
Senior Vice President-Global Supplier Alliance |
|
Harjit Gill
Independent Director |
|
Hemanth Reddy
Chief Strategy Officer |
|
Jan D. de Witte
Independent Director |
|
Jim Ellis
Chief Compliance Officer |
|
John B. Hernandez
Independent Director |
|
Justin G. Leong
Chief Product Officer |
|
Karen Ruth Drexler
Independent Director |
|
Lucile Blaise
Senior VP-Strategy & Business Development |
|
Michael Fliss
Chief Revenue Officer |
|
Michael J. Farrell
Chairman & Chief Executive Officer |
|
Michael Rider
Secretary & Chief Legal Officer |
|
Peter C. Farrell
Chairman-Emeritus |
|
Richard Sulpizio
Independent Director |
|
Ronald R. Taylor
Lead Independent Director |
|
Shane Azzi
Chief Supply Chain Officer |
|
Todd Friedman
Chief Information Security Officer |
|
Vered Keisar
Chief People Officer |
|
Yvonne-Katrin Pucknat
Chief Marketing Officer |